01Approach to the Critical Patient/attcp44

Immediate priorities

›Takotsubo cannot be diagnosed in the ED at first presentation

›Indistinguishable from acute coronary syndrome on initial presentation

›Chest pain, dyspnea, ECG ST changes, and troponin rise overlap completely with ACS

›Diagnosis of takotsubo requires angiography or equivalent to exclude acute coronary occlusion

›Default pathway is the ACS pathway

›Activate STEMI or ACS protocol on clinical suspicion regardless of a takotsubo hunch

›Do not withhold or delay reperfusion evaluation, antiplatelet therapy, or cath lab activation based on clinical suspicion for takotsubo alone

›Angiography demonstrating no culprit occlusive lesion with matching wall motion abnormality is what confirms the diagnosis, not clinical gestalt

›Monitoring and access

›Continuous ECG monitoring with defibrillator pads placed

›QTc prolongation and torsades risk begin immediately

›Two large-bore IV lines

›Central access if vasoactive infusion anticipated

›Arterial line if shock, dynamic outflow obstruction, or vasoactive titration anticipated

›Beat-to-beat pressure tracking needed for phenylephrine or beta-blocker titration

›Time-critical tests

›12-lead ECG within 10 minutes

›STEMI pathway activation if criteria met

›Diffuse T-wave inversion and QTc prolongation over subsequent hours are characteristic but not required at presentation

›High-sensitivity troponin serial strategy

›Modest elevation relative to the extent of wall motion abnormality is a diagnostic clue, not a reason to discount myocardial injury

›Point-of-care ultrasound focused cardiac exam

›Regional wall motion abnormality extending beyond a single coronary territory

›Dynamic left ventricular outflow tract obstruction screen

›Pericardial effusion screen for free wall rupture concern

›Phenotype triage before any vasoactive drug is chosen

›Left ventricular outflow tract obstruction present

02History/hx63

Presentation patterns

›Symptom characterization

›Chest pain

›Acute onset, pressure or tightness quality overlapping with angina

›Dyspnea

›May be the dominant or sole presenting symptom

›Syncope or presyncope

›Suggests outflow tract obstruction or arrhythmia

›Palpitations

›QT-related ventricular ectopy concern

›Timing relative to trigger

›Symptom onset within minutes to hours of an identifiable stressor

›Not required for diagnosis, absent trigger does not exclude takotsubo

Emotional and physical triggers

›Emotional triggers

›Grief or bereavement

›Sudden loss of a loved one

›Acute fear, anger, or interpersonal conflict

›Argument or receiving distressing news

›Financial or legal crisis

›Physical triggers

›Surgery or acute perioperative stress

›Postoperative period is a recognized high-risk window

›Sepsis or acute severe infection

›Asthma or COPD exacerbation

›Major trauma

›Severe pain from an unrelated condition

03Physical Exam/exam29

General and hemodynamics

›Vitals and perfusion

›Tachycardia

›Hypotension

›Narrow pulse pressure supports low output or outflow obstruction

›Hypertension

›Catecholamine surge phase, notably after subarachnoid hemorrhage or pheochromocytoma

›Respiratory status

›Increased work of breathing

›Hypoxemia

›Pulmonary edema from acute LV dysfunction or acute mitral regurgitation

Cardiovascular findings by phenotype

›Outflow tract obstruction findings

›New harsh systolic murmur at the left sternal border

›Increases with Valsalva or standing, decreases with squatting or leg raise

›Murmur intensifies with any inotrope or vasodilator given

›Acute mitral regurgitation findings

›New apical holosystolic murmur radiating to the axilla

›Pulmonary edema disproportionate to the degree of LV dysfunction

›Heart failure findings

›S3 gallop

›Elevated jugular venous pressure

›Peripheral edema

›Free wall rupture and tamponade findings

›Muffled heart sounds

›Elevated jugular venous pressure with hypotension

›Pulsus paradoxus

04Differential Diagnosis/ddx24

Life-threatening causes indistinguishable on initial presentation

›Acute coronary syndrome

›STEMI (ICD-10 I21)

›Culprit occlusive lesion on angiography differentiates from takotsubo

›NSTEMI (ICD-10 I21.4)

›Troponin-to-wall-motion disproportion favors takotsubo but does not confirm it

›Myocarditis (ICD-10 I40)

›Regional wall motion pattern typically does not match a classic apical ballooning distribution

›Cardiac MRI tissue characterization differentiates the two

›Aortic dissection (ICD-10 I71.0)

›Pulse deficit or interarm blood pressure differential

›Pulmonary embolism (ICD-10 I26)

›RV strain pattern rather than LV apical ballooning

›Cardiac tamponade (ICD-10 I31.4)

›Can be the presenting event if free wall rupture has already occurred

Catecholamine-excess and structural mimics

›Pheochromocytoma or paraganglioma catecholamine crisis

›Episodic hypertension, headache, and diaphoresis pattern

›Can itself trigger a takotsubo-pattern cardiomyopathy

›Hypertrophic obstructive cardiomyopathy (ICD-10 I42.1)

›Fixed septal hypertrophy versus takotsubo transient basal hyperkinesis

›Both can produce dynamic outflow tract obstruction

›Acute decompensated heart failure from a known chronic cardiomyopathy (ICD-10 I50.9)

›Prior echo showing chronic regional dysfunction argues against new takotsubo

›Pericarditis (ICD-10 I30)

›Diffuse ST elevation with PR depression rather than regional wall motion abnormality

05Laboratory Tests/lt27

Core biomarkers

›Cardiac injury and stress markers

›High-sensitivity troponin I or T serial testing

›Elevation present but characteristically modest relative to the extent of wall motion abnormality on imaging

›Serial values still needed to exclude a rising pattern consistent with ongoing coronary occlusion

›BNP or NT-proBNP

›Marked elevation, often disproportionately high relative to the troponin rise

›This troponin-to-natriuretic-peptide disparity is a supportive diagnostic feature

›Baseline safety labs for therapy

›Electrolytes with magnesium

›Potassium goal at least 4.0 mmol/l for arrhythmia and torsades risk reduction

›Magnesium goal at least 1.0 mmol/l for arrhythmia and torsades risk reduction

›Creatinine and eGFR

›Contrast planning for angiography and medication dosing

›Coagulation panel

›Baseline before anticoagulation for apical thrombus or embolic risk

Targeted etiologic labs

›Catecholamine-excess screen when clinical suspicion present

›Plasma free metanephrines or urine fractionated metanephrines

›Recurrent episodes, paroxysmal hypertension, or atypical trigger pattern

›CBC and inflammatory markers

›Leukocytosis common in the acute stress response

›CRP elevation nonspecific, does not distinguish from myocarditis alone

PITFALLS and interpretation traps

›Troponin-BNP disproportion misread as reassuring

›A modest troponin with a very high BNP or NT-proBNP reflects severe hemodynamic stress, not a mild event

›Normal or mildly elevated troponin used to exclude significant myocardial dysfunction

›Extensive apical ballooning can coexist with only modest biomarker rise

06Diagnostic Tests/dt54

Scoring Systems

›InterTAK Diagnostic Score

›Components

›Female sex

›Emotional trigger

›Physical trigger

›Absence of ST-segment depression except in lead aVR

›Psychiatric disorder

›Neurologic disorder

›QTc prolongation

›Interpretation

›Higher scores favor takotsubo over acute coronary syndrome

›Intended to raise or lower pretest probability, not to substitute for angiography when ACS cannot be excluded clinically

›InterTAK Diagnostic Criteria

›Transient regional wall motion abnormality as apical ballooning or mid-ventricular, basal, or focal pattern

›Abnormality usually extends beyond a single epicardial coronary territory

›Rare focal variant can be confined to one vascular territory

›Preceding emotional, physical, or combined trigger, or no identifiable trigger

›Neurologic disorders and pheochromocytoma recognized as triggers

›New ECG abnormality present in most cases

›ST elevation, ST depression, T-wave inversion, or QTc prolongation

›Rare cases with no ECG changes

›Marked natriuretic peptide elevation with disproportionately modest troponin rise

›Significant obstructive coronary artery disease does not exclude the diagnosis

›No evidence of infectious myocarditis

MRI

›Cardiac MRI role

›Confirms transient regional wall motion abnormality pattern

07Disposition/dispo21

Admission and level of care

›ICU admission criteria

›Cardiogenic shock or need for vasoactive support

›Left ventricular outflow tract obstruction with hemodynamic compromise

›Sustained ventricular arrhythmia or torsades

›Apical thrombus with embolic event

›Telemetry or monitored bed criteria

›Hemodynamically stable but QTc prolonged

›Continuous monitoring until QTc trends toward baseline

›Stable takotsubo pattern without shock or obstruction

Transfer criteria

›Need for mechanical circulatory support

›VA-ECMO capability, particularly for outflow tract obstruction-associated shock

›Need for emergent cardiothoracic surgery

›Suspected free wall rupture or severe acute mitral regurgitation

Discharge criteria and follow-up

›Discharge not appropriate for the acute index presentation

›Diagnosis requires angiography and imaging confirmation as an inpatient

›Follow-up imaging timing

›Repeat echocardiography at 4 to 6 weeks to confirm recovery of wall motion and LVEF

›Cardiac MRI or repeat echo later if recovery incomplete or diagnosis uncertain

›Outpatient work-up when appropriate

›Psychiatric or neurologic follow-up when a relevant trigger was identified

›Catecholamine-excess evaluation if clinical suspicion for pheochromocytoma persists

08Treatment/t142

Initial ED approach

›Treat as acute coronary syndrome until angiography excludes occlusive disease

›Aspirin PO 160 to 325 mg chewed

›Given per standard ACS protocol before the diagnosis is known

›Standard ACS antiplatelet and anticoagulant pathway per local protocol until a culprit lesion is excluded

›Analgesia

›Fentanyl IV 25 to 50 mcg

›Repeat every 5 to 10 minutes as needed

›Adequate analgesia reduces ongoing catecholamine surge from untreated pain

›Avoid undertreating pain

›Persistent pain perpetuates the catecholamine drive underlying the syndrome

Phenotype-directed hemodynamic management

›Left ventricular outflow tract obstruction present

›Catecholamines and inotropes are contraindicated in this subgroup

›Dobutamine, norepinephrine, epinephrine, and dopamine all worsen the dynamic gradient by increasing basal contractility and reducing LV cavity size

›Phenylephrine IV

›Initiate 0.5 mcg/kg/minute infusion

›Titrate every 3 to 5 minutes to blood pressure and gradient response

›Typical maximum 5 mcg/kg/minute

›Pure alpha-1 agonism raises afterload without inotropy, which reduces the outflow gradient

›Cautious IV fluid boluses

›250 to 500 mL crystalloid aliquots with reassessment

›Increases LV preload and cavity size, which reduces the gradient

›Reassess for pulmonary edema after each aliquot

›Short-acting beta blockade if not in overt heart failure

›Esmolol IV 500 mcg/kg loading dose over 1 minute

›Followed by 50 mcg/kg/minute infusion

›Titrate every 5 to 10 minutes, maximum 200 mcg/kg/minute

›Reduces basal hypercontractility, use with caution if any degree of shock present

›Avoid nitrates and diuretics

›Preload reduction worsens the outflow gradient despite pulmonary congestion

›No outflow tract obstruction

›Standard cardiogenic shock approach applies

›Norepinephrine infusion initiation 0.05 mcg/kg/minute

›Titrate every 2 to 5 minutes to MAP target at least 65 mmHg

›Typical range 0.05 to 1 mcg/kg/minute

›Dobutamine infusion initiation 2.5 mcg/kg/minute

›Titrate to perfusion and cardiac output every 5 to 15 minutes

›Maximum commonly 20 mcg/kg/minute, watch for tachyarrhythmia

›Troubleshooting refractory shock

›If phenylephrine and fluids do not resolve the outflow gradient

›Repeat bedside echo to confirm obstruction status before escalating any inotrope

›Escalate to VA-ECMO rather than adding a catecholamine

›If standard inotrope shock management is not improving perfusion

›Reassess for previously unrecognized outflow tract obstruction before increasing the inotrope dose

Left ventricular outflow tract obstruction specific management

›Mechanism restated for treatment planning

›Basal hyperkinesis with apical akinesis narrows the subaortic outflow tract, often with systolic anterior motion of the mitral valve

›Preferred agents

›Phenylephrine for afterload augmentation, see dosing above

›Volume expansion for preload augmentation, see dosing above

›Esmolol for reduction of basal hypercontractility when hemodynamics allow

›Agents and devices to avoid

›Catecholamine vasopressors and inotropes

›Nitrates and other vasodilators

›Diuretics in the acute obstructive phase

Acute mitral regurgitation

›Mechanism

›Systolic anterior motion of the mitral valve when outflow obstruction is present

›Papillary muscle tethering from apical akinesis when obstruction is absent

›Management when driven by outflow tract obstruction

›Treat the obstruction per the outflow tract obstruction protocol above

›Phenylephrine and volume rather than inotropes or vasodilators

›Management when not driven by outflow tract obstruction

›Standard afterload reduction and cardiogenic shock support as tolerated by blood pressure

›Emergent cardiac surgery evaluation for severe regurgitation with refractory pulmonary edema or shock

Cardiogenic shock and mechanical circulatory support

›Shock recognition

›Cold clammy extremities, oliguria, and rising lactate

›Mechanical circulatory support selection depends on outflow tract obstruction status

›Intra-aortic balloon pump is contraindicated when outflow tract obstruction is present

›Afterload reduction from counterpulsation worsens the dynamic gradient

›VA-ECMO preferred for outflow tract obstruction-associated refractory shock

›Does not depend on native LV ejection and does not traverse the outflow tract

›Impella use requires caution when outflow tract obstruction is present

›A device crossing the obstructed outflow tract can worsen flow acceleration and hemolysis

›Intra-aortic balloon pump or Impella may be considered when no outflow tract obstruction is present and shock is refractory to pharmacologic support

Arrhythmia, QT prolongation, and torsades

›QT monitoring

›Marked QTc prolongation is characteristic in the acute phase

›Continuous telemetry with QTc trend

›Electrolyte correction

›Potassium goal at least 4.0 mmol/l

›Magnesium goal at least 1.0 mmol/l

›Drugs to avoid while QTc is prolonged

›Ondansetron IV

›Even the standard 4 mg IV antiemetic dose prolongs QT, use an alternative antiemetic when QTc is markedly prolonged

›Haloperidol or droperidol

›Azithromycin or fluoroquinolone antibiotics

›Methadone

›Class IA or Class III antiarrhythmics

›Avoid amiodarone as first-line therapy for takotsubo-associated torsades because it also prolongs QT

›Torsades de pointes management

›Magnesium sulfate IV 2 g bolus over 1 to 2 minutes

›May repeat once if recurrent

›Follow with infusion per local protocol

›Overdrive pacing or isoproterenol if refractory

›Increasing heart rate shortens the QT interval

›Defibrillation for pulseless ventricular tachycardia or ventricular fibrillation

›Standard ACLS energy settings

Anticoagulation for apical thrombus

›Risk assessment

›Severe apical akinesis or dyskinesis is the highest-risk finding

›Therapeutic anticoagulation when thrombus is present or embolic risk is high

›Unfractionated heparin IV bolus 60 units/kg

›Maximum bolus 4000 units

›Infusion 12 units/kg/hour, maximum initial 1000 units/hour, titrate to aPTT every 6 hours

›Transition to a direct oral anticoagulant or warfarin once stable

›Apixaban PO 5 mg twice daily as one option

›Duration typically continued until repeat imaging confirms resolution of apical wall motion abnormality, commonly 4 to 12 weeks

›Bleeding risk balance

›Free wall rupture risk in the subacute phase means anticoagulation decisions require ongoing reassessment of wall thinning and effusion on serial imaging

Free wall rupture

›Recognition

›Sudden hemodynamic collapse or pulseless electrical activity, typically in the subacute phase of days after presentation

›POCUS pericardial effusion with hypotension and elevated jugular venous pressure

›Immediate management

›Emergent pericardiocentesis for tamponade physiology

›Emergent cardiothoracic surgery consultation for surgical repair

›Reassess anticoagulation immediately if the patient has been started on it

Iatrogenic harms in routine ED interventions

›Intubation

›Etomidate preferred for induction given hemodynamic neutrality

›Avoid ketamine

›Sympathomimetic effect can worsen catecholamine-driven pathophysiology and any outflow tract obstruction

›Anticipate post-induction hypotension, especially if outflow tract obstruction is present

›Sedation

›Avoid propofol boluses in shock or outflow tract obstruction

›Vasodilation and preload reduction worsen the outflow gradient

›Fluid loading

›Beneficial when outflow tract obstruction is present, increases preload and reduces the gradient

›Requires caution when obstruction is absent and pulmonary edema is present, as in any acute heart failure state

›Oxygen

›Avoid routine high-flow oxygen if normoxic

›Titrate to SpO2 92 to 96 percent for most adults

›Vasopressors

›Catecholamine agents are relatively contraindicated because takotsubo is itself a catecholamine-excess cardiomyopathy

›Exogenous catecholamines can perpetuate myocardial stunning

›Phenylephrine preferred when a vasopressor is needed and outflow tract obstruction is present

›Vasopressin is a catecholamine-sparing alternative to consider for shock refractory to phenylephrine

›Mechanical circulatory support

›Intra-aortic balloon pump contraindicated when outflow tract obstruction is present

›VA-ECMO preferred over device options that traverse the outflow tract in this subgroup

›Anticoagulation

›Indicated for apical thrombus but must be reweighed against free wall rupture risk in the subacute phase

›Fibrinolysis

›Do not withhold fibrinolysis when it is indicated by the standard STEMI pathway and primary PCI is unavailable, the diagnosis cannot be made in the moment

›Fibrinolysis carries bleeding risk without benefit if no coronary thrombus is present, but this can only be known after angiography, not before

›Analgesia

›Adequate opioid analgesia is appropriate and reduces catecholamine drive from untreated pain

›Avoid NSAIDs in the setting of significant acute LV dysfunction or heart failure

09Special Populations/sp22

Pregnancy

›Diagnostic considerations

›Peripartum period, particularly the immediate postpartum period, is a recognized trigger window

›Peripartum cardiomyopathy is the key differential and overlaps clinically

›Treatment considerations

›Phenylephrine is routinely used in obstetric anesthesia and is reasonable when outflow tract obstruction is present

›Avoid ACE inhibitors and ARBs

›Fetal renal toxicity risk

›Maternal-fetal medicine involvement for moderate to severe presentations

Geriatric

›Presentation

›Represents the largest affected demographic, postmenopausal women in particular

›Atypical presentation with dyspnea or confusion rather than classic chest pain

›Treatment considerations

›Higher hypotension risk with beta blockade or afterload-reducing therapy

›Slower titration and closer monitoring

›Renal function fluctuation affecting anticoagulant dosing

Pediatrics

›Presentation

›Rare compared with adult incidence

›Physical or emotional trigger, or a critical illness stress trigger such as sepsis, still applies

›Treatment considerations

›Weight-based vasoactive dosing per pediatric critical care with early PICU involvement

›Verify against current pediatric guideline before use

›Same outflow tract obstruction assessment principle applies before selecting an inotrope or vasopressor

10Background/b32

Epidemiology

›Disease frequency

›Accounts for roughly 1 to 2 percent of patients presenting with suspected ACS with ST elevation

›Postmenopausal women represent approximately 90 percent of cases

›Complication rates

›Left ventricular outflow tract obstruction occurs in approximately 10 to 25 percent of cases

›Cardiogenic shock occurs in approximately 10 to 20 percent of cases

›Apical thrombus occurs in approximately 2 to 8 percent of cases

›In-hospital mortality is comparable to acute coronary syndrome in several large registries, roughly 4 to 5 percent

›Coding and terminology

›ICD-10 Takotsubo syndrome I51.81

Pathophysiology

›Core mechanism

›Catecholamine surge from an emotional, physical, neurologic, or iatrogenic trigger produces transient myocardial stunning

›Proposed mechanisms include catecholamine-induced microvascular dysfunction, direct myocyte toxicity, and outflow tract obstruction with apical stunning from the basal-to-apical gradient in adrenergic receptor density

›Anatomic variants

›Apical ballooning pattern

›Most common form, apex akinetic or dyskinetic with basal hyperkinesis

›Mid-ventricular pattern

›Mid-segment dysfunction with sparing of the apex and base

›Basal or inverted pattern

›Basal segments affected with apical sparing

›Focal pattern

›Isolated segment dysfunction, can mimic a single coronary territory

›Recovery trajectory

›Wall motion abnormality and LVEF typically recover over days to weeks

›Recurrence has been described in a minority of patients

11Patient Discharge Instructions/pdi20

Copy discharge instructions

›Diagnosis explanation

›Stress-related heart muscle weakness, often called broken heart syndrome, usually recovers over weeks

›Medications

›Take all prescribed heart medications exactly as directed

›If aspirin 81 mg daily was prescribed, do not stop it without cardiology guidance

›If an anticoagulant was prescribed for a heart clot, take it exactly as directed and do not stop early

›Activity

›Avoid strenuous exercise until cardiology clears repeat imaging

›Follow-up

›Cardiology follow-up within 1 to 2 weeks

›Repeat echocardiogram at 4 to 6 weeks to confirm recovery

›Return to ED immediately for red flags

›Chest pain lasting more than 10 minutes or at rest

›New or worsening shortness of breath

›Fainting or near-fainting

›Rapid or irregular heartbeat, or heart rate over 120 at rest

›Sudden weakness, numbness, or trouble speaking

›Possible embolic complication from a heart clot

›Sudden severe abdominal or limb pain

›Possible embolic complication from a heart clot

12References/r9

Guidelines and key sources

›International Takotsubo (InterTAK) Diagnostic Criteria and Score, European Heart Journal, Ghadri et al 2018

›Defines the seven-part diagnostic criteria and the clinical scoring tool

›American Heart Association Scientific Statement on takotsubo syndrome, Circulation 2015

›Comprehensive statement on pathophysiology, diagnosis, and management

›European Society of Cardiology position statement on takotsubo syndrome, European Heart Journal

›Diagnostic criteria and management framework from the Heart Failure Association

›International Takotsubo Registry publications

›Multicenter registry data on triggers, complications, and outcomes

›Source file link

Evidence & Review

Evidence & Review